Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.66B |
| Revenue (ttm) | 1.80B |
| Net Income (ttm) | -201.99M |
| Shares Out | n/a |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | 11.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,690 |
| Average Volume | 7,473 |
| Open | 20.88 |
| Previous Close | 21.72 |
| Day's Range | 20.88 - 21.99 |
| 52-Week Range | 10.49 - 129.54 |
| Beta | 0.53 |
| RSI | 51.07 |
| Earnings Date | Feb 25, 2026 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
News
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests
Sarepta Therapeutics recently refinanced a significant portion of its debt, extending maturities and enhancing financial flexibility. Learn why SRPT stock is a Buy.
Sarepta Therapeutics (SRPT) Rises as HHS Expands Newborn Screening
Sarepta Therapeutics (SRPT) Rises as HHS Expands Newborn Screening
Sarepta Therapeutics (SRPT) Announces Convertible Notes Exchange
Sarepta Therapeutics (SRPT) Announces Convertible Notes Exchange
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately ne...
Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential
Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential
SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT Stock News
SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT Stock News
Sarepta (SRPT) Stock Outlook: Wedbush Predicts Potential Growth
Sarepta (SRPT) Stock Outlook: Wedbush Predicts Potential Growth
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.’s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103). • SRPT shares are advancing steadily. Get ...
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.'s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).
Sarepta (SRPT) Advances with FDA Approval for New Dystrophy Treatment Study
Sarepta (SRPT) Advances with FDA Approval for New Dystrophy Treatment Study
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA...
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT)...
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advi...
Sarepta (SRPT) Faces Increased FDA Scrutiny on Elevidys
Sarepta (SRPT) Faces Increased FDA Scrutiny on Elevidys
2 Beaten-Down Stocks to Avoid Right Now
Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to cons...
STATE STREET CORP's Strategic Acquisition of Sarepta Therapeutics Inc Shares
STATE STREET CORP's Strategic Acquisition of Sarepta Therapeutics Inc Shares
Sarepta Shares Jump After FDA Approves Updated Elevidys Label
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulat...
Sarepta Shares Jump After FDA Approves Updated Elevidys Label
Sarepta Therapeutics shares jumped after ... Full story available on Benzinga.com
Sarepta Therapeutics (SRPT) Faces Setback with FDA Warning on Elevidys
Sarepta Therapeutics (SRPT) Faces Setback with FDA Warning on Elevidys
Sarepta (SRPT) Updates Elevidys Prescribing Information with New Safety Measures
Sarepta (SRPT) Updates Elevidys Prescribing Information with New Safety Measures
Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for EL...